Yıl: 2011 Cilt: 5 Sayı: 2 Sayfa Aralığı: 68 - 73 Metin Dili: Türkçe

Konjuge Pnömokok Aşılarında Son Gelişmeler: 13-Valanlı Konjuge Pnömokok Aşısı

Öz:
Streptococcus pneumoniae (pnömokok) tüm dünyada çocuklarda ciddi enfeksiyon hastalıklarına neden olarak ölümlere yol açan önemli bir etkendir. Pnömokok enfeksiyonlarını önlemek üzere 2000 yılında kullanıma sunulan 7 valanlı Konjuge Pnömokok Aşısı (KPA7) aşısı ülkemizde Kasım 2008’den beri ulusal çocuk aşılama takvimine dahil olarak uygulanmaktadır. Dünyanın farklı bölgelerinden gelen veriler KPA7 uygulaması ile bu aşının kapsamına giren serotiplere bağlı olan enfeksiyonların önemli oranlarda azaldığını hatta bazı bölgelerde neredeyse eradike edildiğini göstermektedir. Öte yandan başta 19A serotipi olmak üzere KPA7’de yer almayan serotiplere bağlı enfeksiyonlarda göreceli bir artış görülmektedir. Bu nedenlerle Türkiye dahil birçok ülkede 13 valanlı Konjuge Pnömokok Aşısı (KPA13) uygulamasına geçilmiştir. Bu yazıda KPA7 uygulamasına ve sonuçlarına ilişkin bilgiler ve KPA13’e geçiş konusu gözden geçirilmiştir. (J Pediatr Inf 2011; 5: 68-73)
Anahtar Kelime:

Recent Advances in Pneumococcal Conjugate Vaccines: A 13-Valent Pneumococcal Conjugate Vaccine

Öz:
Streptococcus pneumoniae (pneumococcus) is an important cause of serious infectious diseases, leading to death among children all over the world. The 7-valent pneumococcal conjugate vaccine (PCV7), which was introduced in 2000 to prevent pneumococcal infections, was included in the Childhood National Immunization Program of Turkey in November 2008 and has been used since then. Data from various regions of the world have shown that the frequency of infections due to serotypes included in the PCV7 has substantially decreased, and these infections have almost been eradicated in some regions with PCV7 vaccination. On the other hand, there is a relative increase in the frequency of infections due to serotypes such as 19A, which are not included in the PCV7. Therefore, many countries, including Turkey, have implemented the 13-valent pneumococcal conjugate vaccine (PCV13) immunization program. In this paper, data regarding PCV7 immunization and outcomes,as well as the switch from PCV7 to PCV13, were reviewed. (J Pediatr Inf 2011; 5: 68-73)
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic Evaluation of Serotypes Causing Invasive Pneumococcal Disease among Children Under Five: The Pneumococcal Global Serotype Project. PLoS Medicine 2010; 7:e1000348.
  • Ceyhan M. Çocuklarda pnömokok enfeksiyonları ve aşılama. Çocuk Sağlığı ve Hastalıkları Dergisi 2009; 52: 91-9.
  • O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374: 893-902.
  • McIntosh ED, Fritzell B, Fletcher MA. Burden of paediatric invasive pneumococcal disease in Europe, 2005. Epidemiology and Infection 2007; 135: 644-56.
  • Pletz MW, Maus U, Krug N, Welte T, Lode H. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. International Journal of Antimicrobial Agents 2008; 32: 199-206.
  • Nuorti JP, Whitney CG; Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report. Recommendations and Reports / Centers for Disease Control 2010; 59: 1-18.
  • Schranz J. Pneumococcal conjugate vaccines: what do we know and what do we need? Procedia in Vaccinology 2009; 1: 189-205.
  • Harboe ZB, Valentiner-Branth P, Benfield TL, et al. Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme. Vaccine 2010; 28: 2642-7.
  • Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. The Journal of Infectious Diseases 2010; 201: 32-41.
  • Durando P, Crovari P, Ansaldi F, et al. Universal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria Region, Italy. Vaccine 2009; 27: 3459-62.
  • Guevara M, Barricarte A, Gil-Setas A, et al. Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain. Clinica Microbiology and Infection 2009; 15: 1013-9.
  • Vestrheim DF, Løvoll O, Aaberge IS, et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 2008; 26: 3277-81.
  • Roche PW, Krause V, Cook H, et al. Invasive pneumococcal disease in Australia, 2006. Communicable Diseases Intelligence 2008; 32: 18-30.
  • Lu CY, Huang LM. How many is enough? Will conjugated pneumococcal vaccines with more serotypes and fewer doses work better? Journal of the Formosan Medical Association 2011; 110: 67-9.
  • Ho PL, Chiu SS, Ang I, Lau YL. Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae before and after introduction of 7-valent pneumococcal conjugate vaccine, Hong Kong, 1995-2009. Vaccine 2011; 29: 3270-5.
  • Koshy E, Murray J, Bottle A, Sharland M, Saxena S. Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997-2008. Thorax 2010; 65: 770-4.
  • Jardine A, Menzies RI, McIntyre PB. Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia. The Pediatric Infectious Disease Journal 2010; 29: 607-12.
  • Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007; 369: 1179-86.
  • Zhou F, Shefer A, Kong Y, Nuorti JP. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics 2008; 121: 253-60.
  • Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. The New England Journal of Medicine 2001; 344: 403-9.
  • Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. The New England Journal of Medicine 2006; 354: 1455-63. Erratum in: N Engl J Med 2006; 355: 638.
  • [No authors listed] Changing epidemiology of pneumococcal serotypes after introduction of conjugate vaccine: July 2010 report. Weekly Epidemiological Record 2010; 85: 434-6.
  • Feikin DR, Klugman KP. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clinical Infectious Diseases 2002; 35: 547-55.
  • Jacobs MR, Good CE, Bajaksouzian S, Windau AR. Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine. Clinical Infectious Diseases 2008; 47: 1388-95.
  • Imöhl M, Reinert RR, van der Linden M. Regional differences in serotype distribution, pneumococcal vaccine coverage, and antimicrobial resistance of invasive pneumococcal disease among German federal states. International Journal of Medical Microbiology 2010; 300: 237-47.
  • Imöhl M, Reinert RR, van der Linden M. Adult invasive pneumococcal disease between 2003 and 2006 in North-Rhine Westphalia, Germany: serotype distribution before recommendation for general pneumococcal conjugate vaccination for children _____2 years of age. Clinical Microbiology and Infection 2009; 15: 1008-12.
  • Vestrheim DF, Høiby EA, Bergsaker MR, Rønning K, Aaberge IS, Caugant DA. Indirect effect of conjugate pneumococcal vaccination in a 2+1 dose schedule. Vaccine 2010; 28: 2214-21.
  • Mahjoub-Messai F, Doit C, Koeck JL, et al. Population snapshot of Streptococcus pneumoniae serotype 19A isolates before and after introduction of seven-valent pneumococcal Vaccination for French children. Journal of Clinical Microbiology 2009; 47: 837-40.
  • Rose M, Zielen S. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe. Expert Review of Vaccines 2009; 8: 1351-64.
  • Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011 [Epub ahead of print]
  • Varon E, Janoir C, Gutmann L. Centre National de Référence des Pneumocoques (CNRP). Rapport d’activité 2008.
  • Syriopoulou V, Syrogiannopoulos G, Koutouzis E, et al. Pneumococcal serotypes after the introduction of the heptavalent conjugate vaccine in Greece. 28th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), 4-8 May 2010, Nice, France (Abstract)
  • Yalçin I, Gürler N, Alhan E, et al. Serotype distribution and antibiotic susceptibility of invasive Streptococcus pneumoniae disease isolates from children in Turkey, 2001-2004. European Journal of Pediatrics 2006; 165: 654-7.
  • Ceyhan M, Gürler N, Yaman A, et al. Serotype distribution and molecular epidemiology of invasive Streptococcus pneumoniae isolates among children prior to routine vaccination with seven-valent conjugated pneumococcal vaccine in Turkey. 6th World Congress of the World Society for Pediatric Infectious Diseases (WSPID), 2009, Buenos Aires, Argentina (Poster presentation)
  • Reinert RR, Paradiso P, Fritzell B. Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe. Expert Review of Vaccines 2010; 9: 229-36.
  • Grijalva CG, Pelton SI. A second-generation pneumococcal conjugate vaccine for prevention of pneumococcal diseases in children. Current Opinion in Pediatrics 2011; 23: 98-104
  • Paradiso PR. Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children. Clinical Infectious Diseases 2011; 52: 1241-7.
  • Snape MD, Klinger CL, Daniels ED, et al. Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial. The Pediatric Infectious Disease Journal 2010; 29: 80-90.
  • Gadzinowski J, Albrecht P, Hasiec B, et al. Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccine. Vaccine 2011; 29: 2947-55.
  • Rubin JL, McGarry LJ, Strutton DR, et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine 2010; 28: 7634-43.
APA CEYHAN M (2011). Konjuge Pnömokok Aşılarında Son Gelişmeler: 13-Valanlı Konjuge Pnömokok Aşısı. Çocuk Enfeksiyon Dergisi, 5(2), 68 - 73.
Chicago CEYHAN Mehmet Konjuge Pnömokok Aşılarında Son Gelişmeler: 13-Valanlı Konjuge Pnömokok Aşısı. Çocuk Enfeksiyon Dergisi 5, no.2 (2011): 68 - 73.
MLA CEYHAN Mehmet Konjuge Pnömokok Aşılarında Son Gelişmeler: 13-Valanlı Konjuge Pnömokok Aşısı. Çocuk Enfeksiyon Dergisi, vol.5, no.2, 2011, ss.68 - 73.
AMA CEYHAN M Konjuge Pnömokok Aşılarında Son Gelişmeler: 13-Valanlı Konjuge Pnömokok Aşısı. Çocuk Enfeksiyon Dergisi. 2011; 5(2): 68 - 73.
Vancouver CEYHAN M Konjuge Pnömokok Aşılarında Son Gelişmeler: 13-Valanlı Konjuge Pnömokok Aşısı. Çocuk Enfeksiyon Dergisi. 2011; 5(2): 68 - 73.
IEEE CEYHAN M "Konjuge Pnömokok Aşılarında Son Gelişmeler: 13-Valanlı Konjuge Pnömokok Aşısı." Çocuk Enfeksiyon Dergisi, 5, ss.68 - 73, 2011.
ISNAD CEYHAN, Mehmet. "Konjuge Pnömokok Aşılarında Son Gelişmeler: 13-Valanlı Konjuge Pnömokok Aşısı". Çocuk Enfeksiyon Dergisi 5/2 (2011), 68-73.